These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29727388)

  • 41. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.
    Lee HW; Park SY; Kim SU; Jang JY; Park H; Kim JK; Lee CK; Chon YE; Han KH
    PLoS One; 2016; 11(6):e0157358. PubMed ID: 27284700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
    Wong VW; Petta S; Hiriart JB; Cammà C; Wong GL; Marra F; Vergniol J; Chan AW; Tuttolomondo A; Merrouche W; Chan HL; Le Bail B; Arena U; Craxì A; de Lédinghen V
    J Hepatol; 2017 Sep; 67(3):577-584. PubMed ID: 28506907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes.
    Dioguardi Burgio M; Castera L; Oufighou M; Rautou PE; Paradis V; Bedossa P; Sartoris R; Ronot M; Bodard S; Garteiser P; Van Beers B; Valla D; Vilgrain V; Correas JM;
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1005-1013.e27. PubMed ID: 38072287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center.
    Lupsor Platon M; Stefanescu H; Feier D; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):157-66. PubMed ID: 23799214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A new non-invasive method for assessing steatosis in chronic liver diseases].
    Bakulin IG; Sandler YG; Keyan VA; Rotin DL
    Ter Arkh; 2016; 88(2):49-57. PubMed ID: 27030184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography.
    Recio E; Cifuentes C; Macías J; Mira JA; Parra-Sánchez M; Rivero-Juárez A; Almeida C; Pineda JA; Neukam K
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):905-11. PubMed ID: 23459105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.
    Kim JK; Lee KS; Choi JR; Chung HJ; Jung DH; Lee KA; Lee JI
    Gut Liver; 2015 May; 9(3):405-10. PubMed ID: 25717046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.
    Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z
    Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
    Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
    Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
    Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis.
    Jang JK; Kim SY; Yoo IW; Cho YB; Kang HJ; Lee DH
    Eur Radiol; 2022 Mar; 32(3):2070-2077. PubMed ID: 34549325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
    Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
    J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
    Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
    World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Fouad R; Elbaz T; Abdel Alem S; Elsharkawy A; Negm M; Khairy M; Hassany M; Cordie A; El Akel W; Esmat G
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):882-887. PubMed ID: 29727382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis.
    Ferraioli G; Tinelli C; De Silvestri A; Lissandrin R; Above E; Dellafiore C; Poma G; Di Gregorio M; Maiocchi L; Maserati R; Filice C
    Liver Int; 2016 Dec; 36(12):1860-1866. PubMed ID: 27439331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
    Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
    Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients.
    Fan Y; Wang L; Ding Y; Sheng Q; Zhang C; Li Y; Han C; Dou X
    Aging (Albany NY); 2020 Aug; 12(16):16072-16082. PubMed ID: 32836216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.